After the market closed on Monday, Questcor (QSC) announced financial results for its fiscal 2007 fourth quarter ended December 31, 2007. The Company posted revenue of $27.1 million, an increase of 697% from the year-ago quarter, and net quarterly profit of $0.45 per diluted share (including a tax gain of $0.20 per share). These results compare to revenue of $3.4 million and a net quarterly loss of ($0.06) per diluted share, in the year-ago quarter fourth quarter.
A little noticed event Wednesday, namely Questcor's (AMEX: QSC) announced completion of the repurchase of 2,155,715 shares of outstanding Series A Preferred Stock from Shire Pharmaceuticals, Inc. (NASDAQ: SHPGY), for cash, may have cleared the way for a possible takeover of Questcor by a larger Bio/Pharma rival, specifically Shire itself.
Questcor (QSC) yesterday announced that the Company has completed the repurchase of the outstanding 2,155,715 shares of Series A Preferred Stock from Shire Pharmaceuticals, Inc. for cash of $10.3 million, or $4.80 per share which was the closing price of Questcor's common stock on February 19, 2008.
The Company has been growing cash on the balance sheet at an amazing rate since its new pricing plan was started, and we now estimate that the company had about $39 million in cash on...
The joy of finding a hidden ,
unknown, undervalued treasure is universal in human nature. Whether one
is in search of an antique, or a work of art, or a small Bio/Pharma company that is just turning the corner to large profitability, that search can be a long and tedious one. But, in each case, when finally discovered, the rewards can be tremendous!!
One such hidden, unknown, undervalued Bio/Pharma company that has made an amazing transformation in its model of operation, and that is now leading to a dramatic profit story, is Questcor (Amex: Michael Shulman submits:
Up to now, I've told anyone who would listen that they should avoid
orphan drug companies, and stick with big disease and big
opportunities. But a recent event is changing my mind.
In August, a perennial money loser, Questcor (QSC), announced a
change in the pricing of therapeutic gel Acthar. Acthar is approved to
reduce muscle spasms from multiple sclerosis, but is mostly used
off-label to successfully treat infants who suffer or die from
convulsions. The change was radical and led to a 13-fold increase in
sales.
On Monday, Questcor Pharmaceuticals Inc. (AMEX: QSC) reported great
earnings for their 3rd quarter of $14.8 million and that is compared with
$4 million for the same period a year ago. This pushed the stock passed
its 52-week high of $1.89 to close at $1.92 up 61 cents or over 46% on
over 7.5 million shares traded for the day.
The Net Income that they reported for the quarter was 12 cents per share
versus a loss of 3 cents per share for the same period a year ago. This is
called growth.
After the overwhelming traffic generated from the ?Evaluating the Implosion in Neurocrine? article, it is worth providing some additional data that still offer patience as the best guide rather than trying to be brave and fighting the tape. Neurocrine Biosciences (NBIX) is trading down another 4.8% pre-market and has cracked under the $20 mark.
As noted in yesterday?s article, it is almost always better to patient on biotech implosions than it is to be brave and that is still the case. There should be some value left...
NEW YORK (Market Intellisearch) -- QCOR options saw interesting call activity today. A total of 132 put and 5,839 call contracts were traded raising a low Put/Call volume alert. Today's traded Put ...
by Karla Yeh in Sidewinder Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) saw a big block of near-term calls cross the tape thanks to an investor who could be expressing moderate bearishness on the ...
Questcor Pharmaceuticals, a biopharmaceutical company, has reported a net income of $9.28 million, or $0.14 per diluted share, for the second quarter ended June 30, 2010, compared to $9.31 million ...
(EMAILWIRE.COM, July 30, 2010 ) New York, NY -The Great Atlantic & Pacific Tea Company (NYSE:GAP) soared 24.81% to $3.37 on heavy volume of 4.71 million shares. Over the past 52-weeks, the stock ...
Brilliant Technologies Corporation (PINK: BLLN) gained by 55.5% to close at $0.02 with total traded volume of 1.51 million shares. Brilliant Technologies Corporation is a development-stage company ...
NEW YORK (Market Intellisearch) -- Shares of QCOR crossed above the critical 50-day moving average of $9.88. The location of a stock price when analyzed against the moving average can aid in ...
NEW YORK (Market Intellisearch) -- QCOR options saw interesting call activity today. A total of 62 put and 2,075 call contracts were traded raising a low Put/Call volume alert. Today's traded Put ...
Life Technologies Corp. (NASDAQ:LIFE) fell 5.38% to $42.75 after the he Carlsbad, California-based company's second-quarter net income attributable to controlling interest was $110.6 million or $0 ...
By Chip Brian Below are the top five companies in the Healthcare sector as measured by relative performance. Highest relative performance is a comparison between a share and its peers made to ...
By Seeking Alpha 07/28/10 - 09:26 PM EDT Good day, ladies and gentlemen and thank you for standing by. Welcome to the Questcor Second Quarter 2010 Financial Results Conference Call. During today's ...
Stock News 
The earnings turnaround was a huge...
The Company has been growing cash on the balance sheet at an amazing rate since its new pricing plan was started, and we now estimate that the company had about $39 million in cash on...
